Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive effects of solifenacin versus oxybutynin patch in older women with overactive bladder
ACTRN12611000796987Phase 4Not yet recruiting
- Sponsor
- Bianca Wong
- Start
- Sep 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of solifenacin and oxybutynin in overactive bladder (OAB), sponsored by Bianca Wong. Primary endpoint: Cognitive function. Planned start Sep 2011; status: not yet recruiting.
02
Drugs
solifenacinoxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on ACTRN12611000796987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000796987.